Skip to main content

Outlook Therapeutics, Inc.

OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649989

In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Outlook Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of OTLK: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders63630
Shares20.2M21.2M+922.1K (+4.6%)
Value$50.4M$46.0M−$4.41M (−8.8%)

New holders (8)

Institutions that held Outlook Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to OTLK in Q3 2021
InstitutionSharesValue% of portfolio
Millennium Management LLC960,259$2.08M0.00%
Renaissance Technologies LLC254,781$553.0K0.00%
Susquehanna Fundamental Investments, LLC111,100$241.0K0.00%
SG Americas Securities, LLC44,828$97.0K0.00%
Commonwealth Equity Services, LLC21,522$46.0K0.00%
Infrastructure Capital Advisors, LLC17,300$38.0K0.01%
Walleye Trading LLC15,071$33.0K0.00%
Endurance Wealth Management, Inc.15,000$33.0K0.00%

Sold out (8)

Institutions that held Outlook Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of OTLK in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Jane Street Group, LLC63,967$160.0K
D. E. Shaw & Co., Inc.30,135$75.0K
Alliancebernstein L.P.17,000$42.0K
Virtu Financial LLC14,146$35.0K
XTX Topco Ltd10,871$27.0K
TrinityPoint Wealth, LLC10,000$25.0K
Advisory Services Network, LLC6,055$15.0K
UBS Group AG5,072$13.0K